                <p>Common Antimicrobials Used for Chronic Oral Antimicrobial Suppression (B-III Unless Otherwise Stated
                    in Text)<sup>a,b</sup></p>
            <table>
                <thead>
                    <tr>
                        <th>Microorganism</th>
                        <th>Preferred Treatment</th>
                        <th>Alternative Treatment</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Staphylococci, oxacillin-susceptible </td>
                        <td>Cephalexin 500 mg PO tid or qid <br/>or<br/>Cefadroxil 500 mg PO bid </td>
                        <td>Dicloxacillin 500 mg PO tid or qid<br/>Clindamycin 300 mg PO
                            qid<br/>Amoxicillin-clavulanate 500 mg PO tid </td>
                    </tr>
                    <tr>
                        <td>Staphylococci, oxacillin-resistant </td>
                        <td>Cotrimoxazole 1 DS tab PO bid <br/>Minocycline or doxycycline100 mg PO bid </td>
                        <td> </td>
                    </tr>
                    <tr>
                        <td>β-hemolytic streptococci </td>
                        <td>Penicillin V 500 mg PO bid to qid <br/>or <br/>Amoxicillin 500 mg PO tid </td>
                        <td>Cephalexin 500 mg PO tid or qid </td>
                    </tr>
                    <tr>
                        <td><em>Enterococcus</em> spp, penicillin susceptible </td>
                        <td>Penicillin V 500 mg PO bid to qid <br/>or <br/>Amoxicillin 500 mg PO tid </td>
                        <td> </td>
                    </tr>
                    <tr>
                        <td><em>Pseudomonas aeruginosa</em> </td>
                        <td>Ciprofloxacin 250–500 mg PO bid </td>
                        <td> </td>
                    </tr>
                    <tr>
                        <td>Enterobacteriaceae </td>
                        <td>Cotrimoxazole 1 DS tab PO bid </td>
                        <td>β-lactam oral therapy based on in vitro susceptibilities </td>
                    </tr>
                    <tr>
                        <td><em>Propionibacterium</em> spp </td>
                        <td>Penicillin V 500 mg PO bid to qid <br/>or<br/>Amoxicillin 500 mg PO tid </td>
                        <td>Cephalexin 500 mg PO tid or qid <br/><br/>Minocycline or doxycycline 100 mg PO bid </td>
                    </tr>
                </tbody>
            </table>
            
                    <p>Abbreviations: bid, twice daily; DS, double strength; PO, per oral; qid, 4 times daily; tid, 3
                        times daily.</p>
                    <p><sup>a</sup> Antimicrobial dosage needs to be adjusted based on patients' renal and hepatic
                        function. Antimicrobials should be chosen based on in vitro susceptibility as well as patient
                        drug allergies, intolerances, and potential drug interactions or contraindications to a specific
                        antimicrobial.</p>
                    <p><sup>b</sup> Clinical and laboratory monitoring for efficacy and safety should occur based on the
                        clinical judgment of the clinician caring for the patient. The possibility of prolonged QTc
                        interval and tendinopathy should be discussed and monitored when using fluoroquinolones. The
                        possibility of <em>Clostridium difficile</em> colitis should also be discussed when using any
                        antimicrobial.</p>